• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Entheon Biomedical Corp (OP: ENTBF )

    0.1035 -0.0405 (-28.12%)
    Streaming Delayed Price Updated: 2:18 PM EDT, Jul 10, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 100
    Open 0.1035
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.1440
    Today's Range 0.1035 - 0.1035
    52wk Range 0.0043 - 0.2000
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them
    The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business... 
    Via Benzinga
    PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Poised to Accelerate Its CYB004 Clinical Development Program
    Via Investor Brand Network

    Performance

    YTD
    +1298.65%
    +1298.65%
    1 Month
    +132.58%
    +132.58%
    3 Month
    -13.68%
    -13.68%
    6 Month
    +1001.06%
    +1001.06%
    1 Year
    +295.04%
    +295.04%

    More News

    Read More
    PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Acquires DMT Study Expected to Accelerate Clinical Development Path of CYB004
    Via Investor Brand Network
    Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
    Via Benzinga
    Largest Phase-1 DMT Study In The Netherlands, A Collaboration Between Entheon & Cybin
    Via Benzinga
    Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research
    Via Benzinga
    Entheon Biomedical Announces Non-Brokered Private Placement Financing
    Via Benzinga
    Benzinga's Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th
    Via Benzinga
    Psyched: Psychedelics ETF Launches On NYSE, Psilocybin Trial Approved For Depression, DMT Study Begins
    Via Benzinga
    Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient
    Via Benzinga
    Entheon Biomedical Reports Launching Multiple Studies to Advance Psychedelic-Based Mental Health Treatments
    Via Benzinga
    Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) Featured in Virtual Coverage of Benzinga’s Small Cap Conference
    Via Investor Brand Network
    Compass Pathways 2.0: A New Rally In Psychedelic Stocks?
    Via Talk Markets
    Topics Initial Public Offering
    Exposures Securities Market
    Entheon Biomedical Provides Corporate Update on Studies and Clinical Trials
    Via Newsfile
    Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
    Via Benzinga
    Entheon Biomedical Acquires Lobo Genetics, Inc. in Bid to Strengthen Screening and Treatment Evaluation Tech for Psychedelics
    Via Benzinga
    There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
    Via Benzinga
    Clinical Director of Imperial College's Center for Psychedelic Research Joins Entheon Advisory Board
    Via Newsfile
    Entheon Biomedical Corp. Announces DTC Eligibility
    Via Newsfile
    CORRECTION FROM SOURCE: BTV Examines the Rapidly Expanding Psychedelics Market
    Via Newsfile
    BTV Examines the Rapidly Expanding Psychedelics Market
    Via Newsfile
    Entheon Biomedical Announces Sponsorship of a Clinical Study to Assess the Electroneurophysiologic Effects of Ketamine
    Via Newsfile
    Exposures Product Safety
    Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected
    Via Benzinga
    Entheon Biomedical Corp. Strengthens Its Psychedelic-Assisted Protocols Through Acquisition Of Lobo Genetics
    Via Benzinga
    Entheon Biomedical Corp. Acquires Lobo Genetics Inc.
    Via Newsfile
    Topics Cannabis
    Exposures Cannabis
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.